GEN Exclusives

More »

GEN News Highlights

More »
Oct 23, 2009

EMD Chemicals and MitoSciences to Develop Assays for Drug Toxicity and Mitochondrial Bioactivity

  • EMD Chemicals reported a research and commercial collaboration with MitoSciences related to the detection and profiling of mitochondrial toxicity and activity. The companies will co-develop multiplex immunoassay products for EMD Chemicals' WideScreen™ BeadPlex™ platform.

    The first set of assays is scheduled for availability in early 2010. The kits will be sold to pharmaceutical and biotechnology companies as well as academic institutions. EMD Chemicals and MitoSciences will continue to collaborate to design, create, and release new products that meet the evolving requirements of their customers.

    Under the terms of the agreement, MitoSciences granted EMD Chemicals exclusive rights to a new offering of currently unlicensed mAbs for monitoring mitochondrial toxicity and bioactivity. MitoSciences will work exclusively with EMD Chemicals to validate the new WideScreen™ assays for use in drug-screening applications.

    “MitoSciences has long been aware of the need for multiplex immunoassay panels against mitochondrial and other metabolic proteins,” comments Jean-Paul Audette, president and CEO.

    Christina Shasserre, vp and head of global biosciences for Merck KGaA and EMD Chemicals, adds, “To develop safer drugs and save time and resources in the process, the evaluation of toxicity is a clear focus in preclinical drug development. Testing the effect of drug candidates on mitochondrial processes such as metabolism and replication as an important aspect of toxicity profiling.”


Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »